Business Context and Reporting Period
This Form 8-K is a current report filed by Repligen Corporation on September 3, 2026. The filing addresses the status of the proposed acquisition of BioLife Solutions, Inc. (BioLife), originally announced on July 21, 2026. The report specifically confirms the expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period.
Key Financial Metrics and Transaction Terms
This filing does not contain Repligen's or BioLife's standalone financial performance metrics (revenue, profit, cash flow, or debt). It focuses exclusively on the terms of the pending merger:
- Consideration per BioLife Share: $11.25 in cash plus 0.1442 shares of Repligen common stock.
- Transaction Structure: A two-step merger where BioLife becomes a wholly-owned subsidiary of Repligen.
- Regulatory Status: The HSR Waiting Period expired on September 3, 2026, at 11:59 p.m. Eastern Time.
Material Changes and Progress
The primary material update in this filing is the satisfaction of the regulatory condition regarding the HSR Waiting Period. The transaction remains subject to other customary closing conditions, most notably the approval of the Merger Agreement by BioLife's stockholders. A special meeting of BioLife stockholders to vote on the merger is scheduled for October 5, 2026.
Outlook, Risks, and Contingencies
Management highlights several risks that could prevent the completion of the merger or alter its anticipated benefits:
- Stockholder Approval: The transaction is contingent upon BioLife stockholders adopting the Merger Agreement at the October 5, 2026 meeting.
- Regulatory Conditions: While the HSR period has expired, other regulatory approvals may still be required or could impose conditions affecting the deal.
- Integration and Synergies: Risks include the failure to realize anticipated synergies, revenue growth, or financial benefits due to integration challenges or market conditions.
- Market Risks: Potential overestimation of the cell therapy market size or BioLife's market position.
- Dilution: The issuance of Repligen common stock as part of the consideration may have a dilutive effect on existing shareholders.
Investor Verification Checklist
- Verify the outcome of the BioLife stockholder special meeting scheduled for October 5, 2026.
- Review the definitive proxy statement/prospectus filed on Form S-4 for detailed financial projections and risk factors.
- Monitor for any additional regulatory conditions or delays beyond the HSR expiration.
- Assess the potential dilutive impact of the 0.1442 Repligen shares issued per BioLife share.
- Confirm the final closing date once all remaining conditions are satisfied.